TimesSquare Capital Management LLC Has $34.70 Million Holdings in Amedisys Inc (AMED)
TimesSquare Capital Management LLC trimmed its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 15.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 620,165 shares of the health services provider’s stock after selling 111,505 shares during the quarter. TimesSquare Capital Management LLC owned about 1.83% of Amedisys worth $34,704,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of AMED. American Century Companies Inc. increased its position in Amedisys by 41.4% during the third quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock worth $93,547,000 after buying an additional 489,220 shares during the last quarter. Russell Investments Group Ltd. increased its position in Amedisys by 662.7% during the second quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock worth $17,387,000 after buying an additional 240,513 shares during the last quarter. Balyasny Asset Management LLC acquired a new stake in shares of Amedisys in the second quarter valued at about $7,736,000. Bank of New York Mellon Corp grew its position in shares of Amedisys by 10.8% in the third quarter. Bank of New York Mellon Corp now owns 846,575 shares of the health services provider’s stock valued at $47,375,000 after purchasing an additional 82,247 shares during the last quarter. Finally, Timpani Capital Management LLC acquired a new stake in shares of Amedisys in the second quarter valued at about $4,924,000. 93.94% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have recently issued reports on AMED shares. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $60.00 price target on shares of Amedisys in a research report on Friday, September 15th. Mizuho reaffirmed a “buy” rating and issued a $65.00 price target (up from $55.00) on shares of Amedisys in a research report on Wednesday, November 8th. Benchmark Co. raised Amedisys from a “hold” rating to a “buy” rating and set a $56.00 price target on the stock in a research report on Thursday, November 2nd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $60.00 price target on shares of Amedisys in a research report on Thursday, October 12th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $60.00 price target on shares of Amedisys in a research report on Monday, October 9th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Amedisys presently has an average rating of “Buy” and an average price target of $61.00.
Shares of Amedisys Inc (AMED) opened at $56.12 on Friday. Amedisys Inc has a 1 year low of $38.00 and a 1 year high of $65.91. The firm has a market capitalization of $1,904.54, a PE ratio of 26.85, a P/E/G ratio of 1.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The business had revenue of $380.20 million for the quarter, compared to the consensus estimate of $384.59 million. During the same period last year, the business earned $0.36 earnings per share. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. analysts anticipate that Amedisys Inc will post 2.23 EPS for the current year.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.